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Objective: The in vitro activity of isavuconazole was determined for 1677 Candida and 958 Aspergillus
isolates from 2012 to 2014 with voriconazole as comparator.
Methods: Aspergillus isolates were screened for resistance using azole-agar. Aspergillus isolates that
screened positive and all Candida isolates underwent EUCAST broth microdilution testing. Isolates were
categorized as wild-type (wt) or non-wt, adopting EUCAST epidemiological cut-off values (ECOFFs)
(where available) or wt upper limits (wtULs; two two-fold dilutions above the MIC50). The CYP51A gene
was sequenced for non-wt Aspergillus fumigatus isolates. Itraconazole and posaconazole MICs were
determined for selected Aspergillus isolates with isavuconazole MIC 2 mg/L.
Results: Isavuconazole MIC50 (range) (mg/L) against Candida species were: Candida albicans: 0.03
(0.03 to >4), Candida dubliniensis: 0.03 (0.03), Candida glabrata: 0.03 (0.03e4), Candida krusei:
0.06 (0.03e0.5), Candida parapsilosis: 0.03 (0.03e0.06), Candida tropicalis: 0.03 (0.03 to >4),
Saccharomyces cerevisiae (anamorph: Candida robusta): 0.03 (0.03e0.5). Non-wt isavuconazole/vor-
iconazole MICs were found for C. albicans: 0.8/1.0%, C. dubliniensis: 0/1.8%, C. glabrata: 14.9/9.5%, C. krusei:
2.7/1.4%, C. parapsilosis: 1.7/1.8%, C. tropicalis: 14.3/19.1% and S. cerevisiae: 10.0/0%. Isavuconazole MIC50
(range) (mg/L) against Aspergillus species were: A. fumigatus: 1 (0.125 to >16), Aspergillus niger: 2 (1e8),
Aspergillus terreus: 1 (0.25e8), Aspergillus ﬂavus: 1 (0.5e2), Aspergillus nidulans: 0.125 (0.125e0.25).
Non-wt isavuconazole/voriconazole MICs were found for 13.7/15.2% A. fumigatus, 4.9/0% A. niger and
48.2/22.2% A. terreus.
Conclusion: Isavuconazole displayed broad in vitro activity, similar to that of voriconazole. Up to 15% of
C. glabrata, C. tropicalis and A. fumigatus isolates were non-wt, reﬂecting increased resistance at a
reference centre and technical issues. Signiﬁcant CYP51A alterations were reliably detected applying the
isavuconazole breakpoint. K.M.T. Astvad, Clin Microbiol Infect 2017;23:882
© 2017 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Isavuconazole is a new triazole compound with broad-spectrum
in vitro activity against Aspergillus species and a range of other
medically important yeasts and moulds [1e5]. In 2015 it was
licensed for invasive aspergillosis of adults by the EMA [6] and thef Mycology, Department of
titut, Artillerivej 5, DK-2300
r Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).FDA [7], following the phase III SECURE trial, which demonstrated
non-inferiority compared with voriconazole regarding invasive
mould infections [8]. The standard ﬁrst-line treatment for invasive
aspergillosis has until now been voriconazole [9,10]. Voriconazole
has variable pharmacokinetics and a narrow therapeutic window,
and as such, a proportion of patients are either under-dosed or
experience adverse effects due to toxic levels [11]. Drug interactions
can pose a problem, as can the cyclodextrin content of the intra-
venous formulation when treating patients who have renal
impairment. Isavuconazole provides a welcomed expansion of the
available armamentarium against mould infections and offers aof Clinical Microbiology and Infectious Diseases. This is an open access article under
K.M.T. Astvad et al. / Clinical Microbiology and Infection 23 (2017) 882e887 883favourable proﬁle regarding drug interactions, toxicology, phar-
macokinetics and with a spectrum at least partially including
Mucorales.
Isavuconazole has been shown to be efﬁcacious in oesophageal
candidiasis [12] and has been investigated in the phase III clinical
ACTIVE trial including patients with proven candidaemia or inva-
sive candidiasis. Data evaluation failed to demonstrate non-
inferiority compared with caspofungin but did show a similar
overall success at the end of treatment, overall mortality and good
tolerability (26th European Congress of Clinical Microbiology and
Infectious Diseases, abstract 1239). Although these ﬁndings sup-
port the notion that echinocandins are superior to azoles for the
treatment of candidaemia/invasive candidiasis, isavuconazole may
remain relevant for selected patients with mixed infections,
echinocandin-resistant infections, complicating factors, or for oral
step down.
In this study, we investigated the in vitro susceptibility to isa-
vuconazole compared with voriconazole against a large contem-
porary clinical collection of Aspergillus and Candida isolates
received at the Danish mycology reference centre, including azole-
resistant isolates. MICs were interpreted using the recently estab-
lished EUCAST clinical breakpoints and epidemiological cut-off
values (ECOFFs).
Materials and methods
Isolates
A total of 958 Aspergillus and 1677 Candida isolates, from 683
and 1487 patients, respectively, were included. The collections
contained all isolates from clinical samples or pure cultures
received at the mycology reference laboratory at Statens Serum
Institut for identiﬁcation and susceptibility testing during the cal-
endar years 2012e2014. No ethical restraints apply to studies of
routinely obtained anonymized laboratory data. Identiﬁcation was
done using macro- and micromorphology, supplemented by
thermo-tolerance (incubation at 37C and 43C) and matrix-
assisted laser desorption/ionization time-of-ﬂight mass spectrom-
etry (Bruker, Bremen, Germany) for Candida [13] and by thermo-
tolerance (incubation at 50C) for Aspergillus fumigatus complex
isolates and b-tubulin sequencing [14] for cryptic Aspergillus spe-
cies. The use of the term ‘complex’ is acknowledged for Aspergillus
species other than A. fumigatus, in the absence of detailed molec-
ular identiﬁcation, although for simplicity, it is not used throughout
this manuscript.
Susceptibility testing
EUCAST susceptibility testing was performed according to E.Def
7.2 for Candida [15]. Voriconazole MIC determination was per-
formed for 1647 of 1677 (98.2%) isolates and isavuconazole MIC
determination for all 1677 isolates. For Aspergillus, screening for
azole resistance was gradually introduced in routine laboratory
practice during the collection period, using an azole containing
four-well agar (containing itraconazole: 4 mg/L; voriconazole:
1 mg/L; posaconazole: 0.5 mg/l and an antifungal-free control well
(Balis Laboratorium V.O.F., Bowen-Leeuwen, the Netherlands)) [14].
In brief, 25 mL of a McFarland 0.5 conidial suspension was added to
each well and incubated for 48 hours before reading. Hence,
EUCAST susceptibility testing [15] was performed for 306 of 958
Aspergillus isolates (227 patients) that grew on at least one of the
azole agars, or were non-A. fumigatus isolates. For EUCAST sus-
ceptibility testing, stock solutions (5000 mg/L in dimethyl sulph-
oxide; Sigma-Aldrich, Brøndby, Denmark) of itraconazole (Sigma-
Aldrich), voriconazole (Pﬁzer, Ballerup, Denmark), posaconazole(MSD, Ballerup, Denmark) and isavuconazole (Basilea Pharmaceu-
tica Ltd., Basel, Switzerland) were prepared. Final drug concentra-
tion ranges for isavuconazole and voriconazole were 0.03e4 mg/L
for Candida spp. and 0.125e16 mg/L for Aspergillus spp., respec-
tively. MICswere determined spectrophotometrically at 24 hours as
the lowest concentration giving a 50% growth reduction compared
with an antifungal free control (Candida), or visually applying a no-
growth endpoint after 48 hours of incubation (Aspergillus), as rec-
ommended. EUCAST control strains Candida krusei ATCC 6258 and
Candida parapsilosis ATCC 22019 were routinely included and read
after 24 hours [15]. Except for non-wild-type A. fumigatus isolates,
only isavuconazole and voriconazole MICs are presented in this
report. For interpretation of susceptibility, the following EUCAST
clinical breakpoints were used for A. fumigatus: isavuconazole MIC
1 mg/L (susceptible) and >1 mg/L (resistant); and voriconazole
MIC 1 mg/L (susceptible) and >2 mg/L (resistant).
ECOFF/wild-type deﬁnitions
Isolates were categorized as wild-type (wt) or non-wild-type
(non-wt) adopting the EUCAST ECOFFs. These have been deﬁned
for A. fumigatus, Aspergillus ﬂavus, Aspergillus niger, Aspergillus ter-
reus and Aspergillus nidulans (voriconazole and isavuconazole)
[16,17] and for Candida albicans, Candida glabrata, Candida krusei,
Candida parapsilosis and Candida tropicalis (voriconazole) [18]. For
yeast species without a deﬁned EUCAST ECOFF, a wild-type upper
limit (wtUL) was determined as two two-fold dilution steps above
theMIC50 (MIC50 value is the lowest concentration of the antifungal
at which 50% of the isolates were inhibited) with the exception of
species for which the entire population of MICs were less than or
equal to the lowest concentration tested. In such cases, the lowest
concentration tested was chosen as the wtUL [19].
The MIC50, MIC distribution range and number of isolates with
MICs above the ECOFF/wtUL were determined and compared by
species and antifungal compound.
PCR ampliﬁcation and sequence analysis of the CYP51A gene
Isolates of A. fumigatus classiﬁed as non-susceptible or non-wt
to itraconazole, posaconazole, isavuconazole or voriconazole were
CYP51A sequenced as part of the routine procedures (as previously
described [20]), except for one azole-resistant isolate from 2012,
which was not available for CYP51A sequencing. Additionally, a few
azole-susceptible isolates were sequenced as controls, or if the
patient had previously harboured an azole-resistant A. fumigatus. In
total, 57 A. fumigatus isolates were CYP51A sequenced, 45 of which
had elevated MICs towards isavuconazole or voriconazole.
Nine A. terreus isolates were obtained from one patient with
cystic ﬁbrosis known since 2007 to repeatedly harbour isolates
with an M217I alteration [21]. Eight of these isolates (one wt and
seven resistant) were CYP51A sequenced as previously described
[21].
Results
Isolates and MIC distributions
The normally azole-susceptible Candida species had very low
and comparableMIC distributions for both compounds (Table 1 and
Fig. 1). The following species-speciﬁc wtULs for isavuconazole MIC
distributions were determined: C. albicans, C. dubliniensis,
C. parapsilosis and C. tropicalis: 0.03 mg/L; C. glabrata and Saccha-
romyces cerevisiae: 0.125 mg/L, and C. krusei: 0.25 mg/L. For
C. glabrata, C. krusei, S. cerevisiae and other Candida spp., for which
the MIC distributions were not truncated, the isavuconazole MIC50
Table 1
Total numbers and MIC distributions for Candida species
ID Isolates tested Isavuconazole MIC (mg/L) Voriconazole (mg/L)
(ISA/VRZ) MIC range MIC50 wtUL MIC > wtUL (%) MIC range MIC50 ECOFF wtUL MIC > ECOFF (%)
C. albicans 833/821 0.03e>4 0.03 0.03 0.8 0.03e>4 0.03 0.125 0.03 1.0
C. dubliniensis 56/56 0.03 0.03 0.03 0 0.03e0.25 0.03 0.125 0.03 1.8
C. glabrata 497/487 0.03e4 0.03 0.125 14.9 0.03e4 0.06 1 0.25 9.5
C. krusei 74/73 0.03e0.5 0.06 0.25 2.7 0.125e2 0.25 1 1 1.4
C. parapsilosis 59/56 0.03e0.06 0.03 0.03 1.7 0.03e2 0.03 0.125 0.03 1.8
C. tropicalis 70/68 0.03e>4 0.03 0.03 14.3 0.03e>4 0.03 0.125 0.03 19.1
S. cerevisiae 20/20 0.03e0.5 0.03 0.125 10 0.06e0.5 0.125 NA 0.5 0b
Other Candida spp.a 68/66 0.03e>4 0.03 0.125 11.8 0.03e>4 0.06 NA 0.25 15.2b
Abbreviations: NA, not available; MIC50, theMIC value inhibiting the growth of50% of isolates; wtUL, deﬁned as a two-dilution step above theMIC50 (unless all isolates are at
the truncated lower border of the MIC distribution in which case this MIC value is chosen); ISA, isavuconazole; VRZ, voriconazole.
a Candida species (isavuconazole/voriconazole (if different) MICs): lusitaniae (18/17), kefyr (13/12), fermentati (11), guilliermondii (6), inconspicua (5), pelliculosa, nivariensis,
norvegensis, magnoliae (two each), blankii, metapsilosis, orthopsilosis, palmioleophila, pararugosa, sphaerica, utilis (one each).
b wtUL used instead of the ECOFF as no ECOFF has been determined for these species.
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Fig. 1. MIC distributions for selected Candida species.
K.M.T. Astvad et al. / Clinical Microbiology and Infection 23 (2017) 882e887884and wtULs were one or two dilution steps lower than those for
voriconazole. The percentage of non-wt isolates for the two com-
pounds (isavuconazole/voriconazole) was as follow: C. albicans
(0.8/1.0), C. dubliniensis (0/1.8), C. glabrata (14.9/9.5), C. krusei (2.7/
1.4), C. parapsilosis (1.7/1.8), C. tropicalis (14.3/19.1) and S. cerevisiae
(10.0/0). For voriconazole, the species-speciﬁc wtULs deﬁned in this
study were at least two dilution steps lower than the EUCAST
ECOFFs for all species, with the exception of C. krusei (Table 1).
For the 306 (32%) Aspergillus isolates that underwent EUCAST
susceptibility testing due to a non-fumigatus Aspergillus species
identiﬁcation or growth at the screening agar, the species-speciﬁc
MIC50 values for isavuconazole and voriconazole were again
within one two-fold dilution step of each other (Table 2). Hence, the
isavuconazole MIC distributions were approximately one dilution
step higher for A. fumigatus and A. niger (including A. tubingensis)Table 2
Total numbers and MIC distributions for Aspergillus species
n (%) Isavuconazole MIC (mg/L)
MIC range MIC50 ECOFF
A. fumigatus sensu stricto 211 (69.0) 0.125e>16 1 2
A. niger species complexa 41 (13.4) 1e8 2 4
A. terreus species complex 27 (8.8) 0.25e8 1 1
A. ﬂavus species complex 19 (6.2) 0.5e2 1 2
A. nidulans species complexc 5 (1.6) 0.125e0.25 0.125 0.25
A. calidostus 1 (0.3) 4 NA NA
A. quadrilineatus 1 (0.3) 0.125 NA NA
A. tamarii 1 (0.3) 0.25 NA NA
Abbreviations: NA, not available; MIC50, the MIC value inhibiting the growth of 50% of
Species distribution (isolates submitted to either azole screening or EUCAST susceptibility
A. nidulans var. echinulatus (4), A. tubingensis (2), A. sydowii (2), A. calidoustus (1), A. ochr
a Including the two isolates of A. tubingensis.
b When excluding isolates from a cystic ﬁbrosis patient with a known M217I alteratio
c Including three isolates of A. nidulans var. echinulatus.compared with those for voriconazole and one dilution step lower
for A. nidulans. The percentage of MICs above the ECOFFs for the
two compounds (isavuconazole/voriconazole) were as follows:
A. fumigatus (13.7/15.2); A. niger (4.9/0); A. terreus (48.2/22.2; but
27.8/0 if excluding all isolates from a patient with the previously
detected M217I alteration); A. ﬂavus (0/0) and A. nidulans (0/0)
(Fig. 2). Applying the clinical breakpoints for the 26.3% of
A. fumigatus isolates that underwent EUCAST susceptibility testing,
the susceptibility proﬁles were as follows: isavuconazole: 78.2%
(susceptible; S)/21.8% (resistant; R), voriconazole: 84.8% (S)/6.in-
termediate; 6% (I)/8.5% (R); overall, 24.2% were found to be non-
susceptible to at least one mould-active azole. The overall isavu-
conazole and voriconazole non-susceptibility rates among
A. fumigatus (when including the 592 isolates found susceptible
using the azole agar screenings test) were 5.7% (n ¼ 46) and 4.0%Voriconazole (mg/L)
MIC > ECOFF (%) MIC range MIC50 ECOFF MIC > ECOFF (%)
13.7 0.125e>16 0.5 1 15.2
4.9 0.25e2 1 2 0
48.2/27.8b 0.25e8 1 2 22.2/0b
0 0.5e2 1 2 0
0 0.25e0.5 0.25 1 0
NA >16 NA NA NA
NA 0.125 NA NA NA
NA 1 NA NA NA
isolates.
testing): A. fumigatus (803), A. niger (60), A. terreus (41), A. ﬂavus (35), A. nidulans (6),
aceus (1), A. tamarii (1), A. versicolor (1), and A. quadrilineatus (1).
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one mould-active azole. The detailed triazole MIC and CYP51A
proﬁle for the individual A. fumigatus and A. terreus isolates with an
MIC of 2 mg/L are available in the Supplementary material
(Tables S1 and S2).
CYP51A sequencing
Thirty-two isolates of A. fumigatus isolates with non-wt MIC
values towards voriconazole (n ¼ 31) or isavuconazole (n ¼ 28)
were sequenced (Fig. 2). Isolates with an isavuconazole MIC value
of 4 mg/L also had elevated MIC values for voriconazole and/or at
least one other triazole. In 25 of these isolates (89.3%), CYP51A
mutations known to confer pan-azole resistance were found
(M220I þ V101F (n ¼ 3), TR34/L98H (n ¼ 10), TR34/L98H/S297T/
F495I (n ¼ 4), and TR46/Y121F/T289A (n ¼ 8)) (Fig. 2).
Seventeen isolates had an isavuconazole MIC of 2 mg/L (8.1% of
EUCAST susceptibility tested and 2.1% of all A. fumigatus isolates).
Five of these (29.4%) also had an elevated MIC value towards one of
the other triazoles (see Supplementary material, Table S1). Overall,
six of the 17 isolates (35.3%) harboured a CYP51Amutation (M220K
(n ¼ 1), D262Y (n ¼ 2), F46Y/M172V/E427K (n ¼ 2) and TR34/L98H
(n ¼ 1)). Five isolates with MICs of voriconazole and isavuconazole
1 mg/L were sequenced due to elevated MICs for posaconazole
and itraconazole, four of which harboured G54W (n ¼ 1), P216L
(n ¼ 2) or M220K (n ¼ 1) alterations.
A high number of non-wt A. terreus isolates (z50% for isavu-
conazole) were found (Fig. 2). One patient with cystic ﬁbrosis
contributed with eight resistant isolates and one phenotypically
azole-susceptible isolate; all sequenced resistant isolates had the
M217I alteration, synonymous with the M220I alteration in
A. fumigatus. The phenotypically pan-azole susceptible isolate
harboured an Y491H alteration. In A. fumigatus, this alteration has
been associated with elevated itraconazole MICs [22] but its sig-
niﬁcance in A. terreus is unknown. The eight resistant isolates from
this patient were all identiﬁed as non-wt applying the isavucona-
zole ECOFF, whereas six were non-wt applying the voriconazole
EUCAST ECOFF (see Supplementary material, Table S2).Discussion
Overall, the in vitro activities of isavuconazole and voriconazole
against Candida and Aspergillus isolates were comparable and
consistent with previously published EUCAST [2] and CLSI
[1,5,23,24] MICs. However, for C. krusei and C. glabrata our wt dis-
tributions were two to three dilution steps lower than those re-
ported by CLSI, which may reﬂect the inter-laboratory variability
previously associated with MIC testing of these species (C. glabrata
especially [2]).
Elevated MICs were not uncommon. Indeed, up to 15% of
C. glabrata and C. tropicalis displayed non-wt MICs for isavucona-
zole, whereas this was the case for 5.7% of all included A. fumigatus
isolates. Reports of azole resistance rates in A. fumigatus vary. In an
international surveillance study from 2009 to 2011 the prevalence
in Denmark was 3.3% and equal to the overall average [25]. A
subsequent retrospective laboratory-based documented an in-
crease in azole resistance from 1.4% to 6% in clinical samples in the
time period 2010e2014, suggesting that the resistance rate in
Denmark may be increasing [26].
The proportion of isolates with an isavuconazole MIC of 2 mg/L
(categorized as resistant but still within the wt MIC range) was
comparable to the proportion reported from a recent multicentre
study (~8%; 34/401 isolates), but higher than in the data set used for
setting the EUCAST ECOFFS (3%) [2,17]. This may reﬂect the selected
proportion of isolates undergoing EUCAST susceptibility testing
after azole agar screening (for which a higher proportion of resis-
tance is expected) and the fact that isolates received at a reference
laboratory constitute a selected subset of isolates that may not be
fully representative for the national epidemiology.
All A. fumigatus isolates with CYP51A mutations consistently
known to confer voriconazole or pan-azole resistance were classi-
ﬁed as resistant applying the isavuconazole breakpoint. One
M220K alteration resulted in discreet MIC elevations (isavucona-
zole MIC of 2 mg/L), but whether this is clinically relevant is un-
clear. However, one TR34/L98H was found within the wt MIC range
(isavuconazole MIC of 2 mg/L). In comparison, one TR34/L98H/
S297T/F495I was classiﬁed as voriconazole susceptible, illustrating
K.M.T. Astvad et al. / Clinical Microbiology and Infection 23 (2017) 882e887886that perfect discrimination of susceptible and mutant isolates is
challenging to achieve due to the overlapping MIC distributions for
wt and mutant isolates for both compounds.
For A. terreus, we found a high proportion of non-wt isolates for
both drugs and notably higher (27.8%) for isavuconazole compared
with voriconazole (0%), even after excluding a patient known to
harbour isolates with an M217I alteration. These differences are
most likely not reﬂecting efﬁcacy differences between the two
compounds, but rather technical issues related to MIC testing and
categorization, as the MIC distributions were symmetric with an
MIC50 of 1 mg/L and produced an almost identical categorization if
an isavuconazole ECOFF of 2 mg/L was applied.
Two A. niger complex isolates (4.9%) were non-wt for isavuco-
nazole, one of which belonged to the intrinsically less susceptible
cryptic species A. tubingensis. This is in line with a previous report
and within the percentage of wild-type isolates expected to be
above the ECOFF [2,27].
Technical challenges regarding MIC endpoint reading were
encountered. For C. tropicalis, we found a tail of high MIC values
for both compounds, primarily consisting of isolates with trailing
phenotype, i.e. with residual growth over a broad range of MIC
values. Whether such isolates are truly resistant is still unresolved
and the phenomenon implies a risk of variation in MIC and
random susceptibility classiﬁcation. Moreover, the growth curves
for C. krusei were less steep for isavuconazole around the 50%
growth inhibition target, resulting in less reproducible MIC
determination (and less well-deﬁned normal distributions for
isavuconazole than for voriconazole). This may, at least in part,
explain the higher degree of inter-laboratory variation previously
observed for this species [2]. Finally, the MIC distributions for the
two compounds against A. terreus mirrored one another with a
modal MIC of 1 mg/L. In contrast, the modal MIC from the data set
used to set EUCAST ECOFFs for isavuconazole was 0.5 mg/L and
CLSI modal MICs are reported to be 0.25e0.5 mg/L [1,23]. These
discrepancies (± one dilution) are all within the expected varia-
tion for susceptibility testing, yet lead to interpretative disagree-
ment when a restrictive endpoint is adopted. Of note, inter-
laboratory discrepancies in MIC testing of A. terreus in particular
have previously been reported, but the underlying mechanism
remain unclear [2].
Our study has limitations. For Candida species, the truncation of
the MIC distribution interfered with deﬁnitive MIC and wtUL
determination, particularly for the normally azole-susceptible
species. The discrepancy between wtULs for isavuconazole and
voriconazole ECOFFs did result in some non-wt classiﬁcation dif-
ferences. For C. glabrata, the difference is most likely artiﬁcial and
due to our strict deﬁnition of an wtUL, in combination with a
truncatedMIC interval. If we applied our strict deﬁnition of anwtUL
on voriconazole, 15% of isolates would be non-wt for both com-
pounds, suggesting comparable activity of the two.
One concern could be that we may have overlooked resistant
A. fumigatus isolates, as conﬁrmatory EUCAST AFST was only per-
formed for isolates that grew on the screening agar (in which isa-
vuconazole is not incorporated). We have EUCAST susceptibility
tested one-quarter of all A. fumigatus isolates as they were origi-
nally screening positive, but only conﬁrmed resistance in under
one-quarter. Moreover, a recent multicentre study conﬁrmed a
speciﬁcity of 95%e100% (27th European Congress of Clinical
Microbiology and Infectious Diseases, abstract P1750). On this
background, we ﬁnd it unlikely that the isavuconazole resistance
rate was underestimated despite not performing EUCAST micro-
dilution testing on all isolates. However, as isavuconazole was not
licensed in our country in the years of isolate collection, it remains
to be seen if isavuconazole mono-resistance mutations may occur
once the compound is in clinical use.In conclusion, the in vitro activity of voriconazole and isavuco-
nazole is similar, with observed differences in Candida species be-
ing primarily due to methodological issues. This suggests that
isavuconazole will be a promising new alternative in most cases
where voriconazole is indicated, particularly in patients with
invasive aspergillosis, and that susceptibility testing is important
for clinical management.
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